Research news

Large magnifying glass on light blue background

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia

Following clearance by the US drug regulatory body the Food and Drug Administration (FDA) in July 2023, the pharmaceutical company Larimar Therapeutics has completed full enrolment and dosing of the […]

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia Read More »

New study shows impacts of FA on daily life, wellbeing, and relationships in those with FA and their caregivers

Friedreich's ataxia, Research News / Scarlett Parr-Reid

Findings from a recent study, ‘Health-related quality of life in Friedreich Ataxia: A study of impacts on patients and caregivers’, were presented at the International Society for Pharmacoeconomics and Outcomes

New study shows impacts of FA on daily life, wellbeing, and relationships in those with FA and their caregivers Read More »

Results of Ataxia UK-funded study assessing speech therapy in people with progressive ataxias

Cerebellar ataxia, Friedreich's ataxia, Research News, SCAs / Scarlett Parr-Reid

Research by Prof Anja Lowit and her team at Strathclyde University, Glasgow, studying the effectiveness of a new type of speech therapy for some progressive ataxias, has shown some promising

Results of Ataxia UK-funded study assessing speech therapy in people with progressive ataxias Read More »

Larimar Therapeutics announces progress of the Nomlabofusp (CTI-1601) trial for Friedreich’s ataxia

New study shows impacts of FA on daily life, wellbeing, and relationships in those with FA and their caregivers

Results of Ataxia UK-funded study assessing speech therapy in people with progressive ataxias

Call Us

Email Us

Get Social